Navigation Links
Hepatitis C therapy: Inhibiting newly discovered microDNA molecule

Last fall Dr. Peter Sarnow and a team of Stanford University scientists reported that the hepatitis C virus needs a specific microRNA, named miR-122, in order to replicate in cultured liver cells.

When the scientists inactivated the microRNA, the amount of hepatitis C virus RNA was reduced by approximately 80 percent. The discovery was widely heralded for its potential to develop new antiviral agents against hepatitis C, the most common blood-borne viral infection in the United States, affecting more than 2.5 million Americans and a staggering 170 million people worldwide. The best treatment regimens now available are difficult, expensive, laden with serious side effects and effective in only half the cases.

Dr. Sarnow discusses the most recent findings in this work on April 5 at Experimental Biology 2006 in San Francisco. His presentation is part of the scientific program of the American Society for Biochemistry and Molecular Biology.

MicroRNAs, or miRNAs for short, are small RNA molecules that regulate genes in many plant and animal species. Although miRNAs were not discovered until the mid-1990, a growing number of studies suggest that over 300 human genes encode microRNAs and that these microRNAs may control gene expression for as much as a third of the human genome, acting as key regulators of processes as diverse as early development, cell proliferation and cell death, and cell differentiation. Some miRNAs are located throughout the body, while others are found only in specific tissue. The miRNA whose surprising new role was discovered by Dr. Sarnow and his colleagues is located only in the liver. The Sarnow team found that miR-122 binds to a specific noncoding binding region in virus, called target 5' NCR. This is the first example of an animal RNA that interacts with its target 5' NCR, and opens an interesting possibility that other viral 5' NCRs are similarly targeted by different miRNAs.


'"/>

Source:Federation of American Societies for Experimental Biology


Page: 1

Related biology news :

1. Scientists Replicate Hepatitis C Virus in Laboratory
2. Norovirus, AIDS vaccine and Hepatitis Virus
3. UCLA study assesses cost-effectiveness of Hepatitis B drugs
4. Natural Killers Could Lead to New Hepatitis Treatments
5. FDA Approves New Treatment for Chronic Hepatitis B
6. Identification of specific genes predicts which patients will respond to Hepatitis C treatment
7. Hepatitis C responds best to combo of ribavirin and interferon, study concludes
8. Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied
9. Hepatitis C complicated by morphine withdrawal
10. Hepatitis B accounts for 40 percent of missing Asian women
11. Hepatitis E takes a piggyback
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we spend ... recovery so we need to do it well. Inadequate sleep levels have been found ... pressure, stroke, diabetes, and even cancer. Maybe now is the best time ... could help them to manage their sleep quality? Continue ... ...
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only way to ... technology experience. All three tenets were on display at the 2nd Annual DrugDev User ... 40 sponsor, CRO and site organizations to discuss innovation and the future of clinical ...
(Date:12/2/2016)... , December 2, 2016 The ... 2021, growing at a CAGR of 7.3% during the forecast period ... hospitals and diagnostic laboratories segment accounted for the largest share of ... ... report on global immunohistochemistry (IHC) market spread across 225 pages, profiling ...
(Date:11/30/2016)... Nov. 30, 2016 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is excited to announce the formation of ... developing preclinical ophthalmology assets through proof of concept. ... created by Portage Pharmaceuticals Limited and being developed ... surface and anterior segment diseases. This agent has ...
Breaking Biology Technology: